The nation of Zimbabwe has rejected a significant American healthcare agreement valued at $367m (272 million pounds) spanning five years because of Washington's demand for confidential information.
This rejection became public following a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government spokesman later clarified that the US was requesting biological samples for research and profit but refused to share the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued talks to secure a agreement acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Background
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were filed about the security of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
Based on statements, Sixteen African countries have to date signed these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Put simply, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be available to our population if a future health crisis emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its push of one-on-one deals were disrupting structures already set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing system created to manage potential global health emergencies.
"This system is designed to ensure that when a nation provides its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how subsequent co-operation could be structured in a way that honours the independence and interests of each country."
Health Experts Response
Medical experts said it recognised the official position, but suggested that talks need to persist given that much of the nation's Aids initiatives were funded by external financing.
"Where specific concerns arise, such as those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," it added.
The halted deal highlights the ongoing tensions between receiving crucial international aid and protecting local interests in an ever more data-driven world.